BACKGROUND: The no objective testing rule (NOTR) is a decision aid designed to safely identify emergency department (ED) patients with chest pain who do not require objective testing for coronary artery disease. OBJECTIVES: The objective was to validate the NOTR in a cohort of U.S. ED patients with acute chest pain and compare its performance to the HEART Pathway. METHODS: A secondary analysis of 282 participants enrolled in the HEART Pathway randomized controlled trial was conducted. Each patient was classified as low risk or at risk by the NOTR. Sensitivity for major adverse cardiac events (MACE) at 30 days was calculated in the entire study population. NOTR and HEART Pathways were compared among patients randomized to the HEART Pathway in the parent trial using McNemar's test and the net reclassification improvement (NRI). RESULTS:Major adverse cardiac events occurred in 22/282 (7.8%) participants, including no deaths, 16/282 (5.6%) with myocardial infarction (MI), and 6/282 (2.1%) with coronary revascularization without MI. NOTR was 100% (95% confidence interval [CI] = 84.6%-100%) sensitive for MACE and identified 78/282 patients (27.7%, 95% = CI 22.5-33.3%) as low risk. In the HEART Pathway arm (n = 141), both NOTR and HEART Pathway identified all patients with MACE as at risk. Compared to NOTR, the HEART Pathway was able to correctly reclassify 27 patients without MACE as low risk, yielding a NRI of 20.8% (95% CI = 11.3%-30.2%). CONCLUSIONS: Within a U.S. cohort of ED patients with chest pain, the NOTR and HEART Pathway were 100% sensitive for MACE at 30 days. However, the HEART Pathway identified more patients suitable for early discharge than the NOTR.
RCT Entities:
BACKGROUND: The no objective testing rule (NOTR) is a decision aid designed to safely identify emergency department (ED) patients with chest pain who do not require objective testing for coronary artery disease. OBJECTIVES: The objective was to validate the NOTR in a cohort of U.S. ED patients with acute chest pain and compare its performance to the HEART Pathway. METHODS: A secondary analysis of 282 participants enrolled in the HEART Pathway randomized controlled trial was conducted. Each patient was classified as low risk or at risk by the NOTR. Sensitivity for major adverse cardiac events (MACE) at 30 days was calculated in the entire study population. NOTR and HEART Pathways were compared among patients randomized to the HEART Pathway in the parent trial using McNemar's test and the net reclassification improvement (NRI). RESULTS: Major adverse cardiac events occurred in 22/282 (7.8%) participants, including no deaths, 16/282 (5.6%) with myocardial infarction (MI), and 6/282 (2.1%) with coronary revascularization without MI. NOTR was 100% (95% confidence interval [CI] = 84.6%-100%) sensitive for MACE and identified 78/282 patients (27.7%, 95% = CI 22.5-33.3%) as low risk. In the HEART Pathway arm (n = 141), both NOTR and HEART Pathway identified all patients with MACE as at risk. Compared to NOTR, the HEART Pathway was able to correctly reclassify 27 patients without MACE as low risk, yielding a NRI of 20.8% (95% CI = 11.3%-30.2%). CONCLUSIONS: Within a U.S. cohort of ED patients with chest pain, the NOTR and HEART Pathway were 100% sensitive for MACE at 30 days. However, the HEART Pathway identified more patients suitable for early discharge than the NOTR.
Authors: Judd E Hollander; Andra L Blomkalns; Gerard X Brogan; Deborah B Diercks; John M Field; J Lee Garvey; W Brian Gibler; Timothy D Henry; James W Hoekstra; Brian R Holroyd; Yuling Hong; J Douglas Kirk; Brian J O'Neil; Raymond E Jackson; Tom Aufderheide; Andra L Blomkalns; Gerard X Brogan; James Christenson; Sean Collins; Deborah B Diercks; Francis M Fesmire; J Lee Garvey; Gary B Green; Christopher J Lindsell; W Frank Peacock; Charles V Pollack; Robert Zalenski Journal: Ann Emerg Med Date: 2004-12 Impact factor: 5.721
Authors: A Jacob Six; Louise Cullen; Barbra E Backus; Jaimi Greenslade; William Parsonage; Sally Aldous; Pieter A Doevendans; Martin Than Journal: Crit Pathw Cardiol Date: 2013-09
Authors: Pamela L Owens; Marguerite L Barrett; Teresa B Gibson; Roxanne M Andrews; Robin M Weinick; Ryan L Mutter Journal: Ann Emerg Med Date: 2010-01-15 Impact factor: 5.721
Authors: Simon A Mahler; Chadwick D Miller; Judd E Hollander; John T Nagurney; Robert Birkhahn; Adam J Singer; Nathan I Shapiro; Ted Glynn; Richard Nowak; Basmah Safdar; Mary Peberdy; Francis L Counselman; Abhinav Chandra; Joshua Kosowsky; James Neuenschwander; Jon W Schrock; Stephen Plantholt; Deborah B Diercks; W Frank Peacock Journal: Int J Cardiol Date: 2012-10-30 Impact factor: 4.164
Authors: B E Backus; A J Six; J C Kelder; M A R Bosschaert; E G Mast; A Mosterd; R F Veldkamp; A J Wardeh; R Tio; R Braam; S H J Monnink; R van Tooren; T P Mast; F van den Akker; M J M Cramer; J M Poldervaart; A W Hoes; P A Doevendans Journal: Int J Cardiol Date: 2013-03-07 Impact factor: 4.164
Authors: Alan B Storrow; Robert H Christenson; Richard M Nowak; Deborah B Diercks; Adam J Singer; Alan H B Wu; Erik Kulstad; Frank LoVecchio; Christian Fromm; Gary Headden; Tracie Potis; Christopher J Hogan; Jon W Schrock; Daniel P Zelinski; Marna R Greenberg; James C Ritchie; Janna S Chamberlin; Kurtis R Bray; Daniel W Rhodes; Deirdre Trainor; Dawn Holmes; Paula C Southwick Journal: Clin Biochem Date: 2014-09-04 Impact factor: 3.281
Authors: Simon A Mahler; Robert F Riley; Brian C Hiestand; Gregory B Russell; James W Hoekstra; Cedric W Lefebvre; Bret A Nicks; David M Cline; Kim L Askew; Stephanie B Elliott; David M Herrington; Gregory L Burke; Chadwick D Miller Journal: Circ Cardiovasc Qual Outcomes Date: 2015-03-03
Authors: Jaimi H Greenslade; William Parsonage; Martin Than; Adam Scott; Sally Aldous; John W Pickering; Christopher J Hammett; Louise Cullen Journal: Ann Emerg Med Date: 2015-09-10 Impact factor: 5.721